{"name":"Swedish Orphan Biovitrum","slug":"swedish-orphan-biovitrum","ticker":"","exchange":"","domain":"swedishorphanbiovitrum.com","description":"","hq":"Stockholm","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":300000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Alprolix","genericName":"EFTRENONACOG ALFA","slug":"eftrenonacog-alfa","revenue":300000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":300000000,"percentOfTotal":100,"drugCount":13,"colorKey":"oncology","drugs":[{"name":"Alprolix","genericName":"EFTRENONACOG ALFA","slug":"eftrenonacog-alfa","indication":"Hereditary factor IX deficiency disease","status":"marketed","revenue":300000000},{"name":"Vitamin B12-ratiopharm N, injection solution","genericName":"Vitamin B12-ratiopharm N, injection solution","slug":"vitamin-b12-ratiopharm-n-injection-solution","indication":"Other","status":"phase_1"},{"name":"Physician's Choice medications","genericName":"Physician's Choice medications","slug":"physician-s-choice-medications","indication":"Multiple Indications","status":"phase_3"},{"name":"Alprolix","genericName":"Alprolix","slug":"alprolix","indication":"Hereditary factor IX deficiency disease","status":"marketed"},{"name":"ELOCTA","genericName":"ELOCTA","slug":"elocta","indication":"Other","status":"marketed"},{"name":"Elocta","genericName":"EFMOROCTOCOG ALFA","slug":"efmoroctocog-alfa","indication":"Hereditary factor VIII deficiency disease","status":"marketed"},{"name":"Emapalumab-Lzsg","genericName":"Emapalumab-Lzsg","slug":"emapalumab-lzsg","indication":"Primary hemophagocytic lymphohistiocytosis","status":"discontinued"},{"name":"Nitisinone in Arm A","genericName":"Nitisinone in Arm A","slug":"nitisinone-in-arm-a","indication":"Other","status":"phase_1"},{"name":"Nitisinone in Arm B","genericName":"Nitisinone in Arm B","slug":"nitisinone-in-arm-b","indication":"Other","status":"phase_1"},{"name":"Nitisinone, capsule","genericName":"Nitisinone, capsule","slug":"nitisinone-capsule","indication":"Other","status":"phase_1"},{"name":"SEL-212 high-dose","genericName":"SEL-212 high-dose","slug":"sel-212-high-dose","indication":"Refractory gout (severe, uncontrolled hyperuricemia in patients inadequately responsive to conventional urate-lowering therapy)","status":"phase_3"},{"name":"SOBI003","genericName":"SOBI003","slug":"sobi003","indication":"Other","status":"phase_1"},{"name":"rhBSSL","genericName":"rhBSSL","slug":"rhbssl","indication":"Other","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Kepivance (Palifermin)","genericName":"Kepivance (Palifermin)","slug":"kepivance-palifermin","indication":"Oral mucositis in patients with hematologic malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation","status":"marketed"},{"name":"Palifermin before and after","genericName":"Palifermin before and after","slug":"palifermin-before-and-after","indication":"Chemotherapy-induced oral mucositis in patients receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Palifermin before only","genericName":"Palifermin before only","slug":"palifermin-before-only","indication":"Oral mucositis in patients receiving myeloablative chemotherapy and hematopoietic stem cell transplantation","status":"phase_3"},{"name":"SEL-212 low-dose","genericName":"SEL-212 low-dose","slug":"sel-212-low-dose","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Placebo matching Pegcetacoplan","genericName":"Placebo matching Pegcetacoplan","slug":"placebo-matching-pegcetacoplan","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_3"}]}],"pipeline":[{"name":"Alprolix","genericName":"EFTRENONACOG ALFA","slug":"eftrenonacog-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary factor IX deficiency disease"],"catalyst":""},{"name":"Vitamin B12-ratiopharm N, injection solution","genericName":"Vitamin B12-ratiopharm N, injection solution","slug":"vitamin-b12-ratiopharm-n-injection-solution","phase":"phase_1","mechanism":"Vitamin B12-ratiopharm N facilitates the metabolism of homocysteine and methylmalonyl-CoA by acting as a cofactor for methionine synthase and methylmalonyl-CoA mutase.","indications":[],"catalyst":""},{"name":"Kepivance (Palifermin)","genericName":"Kepivance (Palifermin)","slug":"kepivance-palifermin","phase":"marketed","mechanism":"Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes.","indications":["Oral mucositis in patients with hematologic malignancies receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation"],"catalyst":""},{"name":"Palifermin before only","genericName":"Palifermin before only","slug":"palifermin-before-only","phase":"phase_3","mechanism":"Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes.","indications":["Oral mucositis in patients receiving myeloablative chemotherapy and hematopoietic stem cell transplantation","Mucositis prevention in cancer patients undergoing high-dose chemotherapy or chemoradiation"],"catalyst":""},{"name":"Physician's Choice medications","genericName":"Physician's Choice medications","slug":"physician-s-choice-medications","phase":"phase_3","mechanism":"Physician's Choice medications are a class of treatments that provide a choice between different medications for a specific condition.","indications":["Multiple Indications"],"catalyst":""},{"name":"Alprolix","genericName":"Alprolix","slug":"alprolix","phase":"marketed","mechanism":"Small molecule","indications":["Hereditary factor IX deficiency disease"],"catalyst":""},{"name":"ELOCTA","genericName":"ELOCTA","slug":"elocta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Elocta","genericName":"EFMOROCTOCOG ALFA","slug":"efmoroctocog-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Emapalumab-Lzsg","genericName":"Emapalumab-Lzsg","slug":"emapalumab-lzsg","phase":"discontinued","mechanism":"12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted.","indications":["Primary hemophagocytic lymphohistiocytosis"],"catalyst":""},{"name":"Nitisinone in Arm A","genericName":"Nitisinone in Arm A","slug":"nitisinone-in-arm-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nitisinone in Arm B","genericName":"Nitisinone in Arm B","slug":"nitisinone-in-arm-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nitisinone, capsule","genericName":"Nitisinone, capsule","slug":"nitisinone-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Palifermin before and after","genericName":"Palifermin before and after","slug":"palifermin-before-and-after","phase":"phase_3","mechanism":"Palifermin is a keratinocyte growth factor (KGF) receptor agonist that stimulates epithelial cell proliferation and differentiation to protect and repair oral mucosa.","indications":["Chemotherapy-induced oral mucositis in patients receiving myeloablative chemotherapy followed by hematopoietic stem cell transplantation"],"catalyst":""},{"name":"Placebo matching Pegcetacoplan","genericName":"Placebo matching Pegcetacoplan","slug":"placebo-matching-pegcetacoplan","phase":"phase_3","mechanism":"This is a placebo control arm matching the active drug pegcetacoplan, which is a complement C3 inhibitor that blocks the alternative complement pathway.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)","C3 glomerulopathy","Post-transplant thrombotic microangiopathy"],"catalyst":""},{"name":"SEL-212 high-dose","genericName":"SEL-212 high-dose","slug":"sel-212-high-dose","phase":"phase_3","mechanism":"SEL-212 is a combination therapy that pairs a uricase enzyme with an immunosuppressant to lower uric acid levels while preventing immune reactions against the enzyme.","indications":["Refractory gout (severe, uncontrolled hyperuricemia in patients inadequately responsive to conventional urate-lowering therapy)"],"catalyst":""},{"name":"SEL-212 low-dose","genericName":"SEL-212 low-dose","slug":"sel-212-low-dose","phase":"phase_3","mechanism":"SEL-212 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"SOBI003","genericName":"SOBI003","slug":"sobi003","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"rhBSSL","genericName":"rhBSSL","slug":"rhbssl","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOd0M1MUZwMVlMekNSZlNlTW9BVU5UMDQwS0NpLTR3cC0wWnVEMnhFN1lrUE9kbUtSSy1jYXRZNFhicHRheFZDdFEzVVBCVEYyeTQ5RlJZdTdycmYyRU4zOU5qZm5aQ2o4bE5LWW92ZnB6OEdEemxJZDRfR24zMHRDd21kY3VQRFl1SEtsRkZlcV9JV1EtMkZz?oc=5","date":"2026-02-05","type":"pipeline","source":"The Pharma Letter","summary":"Sobi reports 4th-qrt and full year 2025 results - The Pharma Letter","headline":"Sobi reports 4th-qrt and full year 2025 results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBVNkduTkRNYi1FeENUM2t0T1l5dWV0MWRRc3prWmNnMEdYOWtqWFBsa2JibktxM2NHanJ2NW1KeWxpSXNzYThGZS1ZVmhIaXNIOFlv?oc=5","date":"2026-01-16","type":"pipeline","source":"FirstWord Pharma","summary":"EU expands Sobi's Aspaveli for rare kidney diseases - FirstWord Pharma","headline":"EU expands Sobi's Aspaveli for rare kidney diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE4wbzlzSWM2WGhzcy1TbVVWYXhqRnd4bnduUnZ1Z2N4LTQxY21ULU5pUTdsQTlqZ3MycWxuRTJUUFBkX3lYeUM2cjJhNW03dWdpeUJRLUR5eHUzcVl1NnZkTWJ0YmU1SWxzbUFteFVzSHNfbUl0N0FaUGpJSQ?oc=5","date":"2025-12-22","type":"trial","source":"Triodos Investment Management","summary":"case study Pharma for children: closing the gap - Triodos Investment Management","headline":"case study Pharma for children: closing the gap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE43TGlpSXJubENFMzVjUjhST2pFek9hS1M1OHcyZy1oRlJzc2VaUlRJNUt4TXJHWXpQY3htai00ZElGbUZnRmVCeUlfc2h3T2lzZ21jVnRqaXV0WEI3aEwxemRDVXpfeVNzVmdiakhhYw?oc=5","date":"2025-12-15","type":"deal","source":"medwatch.com","summary":"Sweden's Sobi acquires US biotech for up to USD 1.5bn - medwatch.com","headline":"Sweden's Sobi acquires US biotech for up to USD 1.5bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWEdDN3MzNHQyakxCM1JfUGZ4WllmNFFvWG5vSGFseHZ1T1hCNm94T05LYm5YVUVORXRqdnE2TzBsaFg1LUh0Y1lxRXV5cWE1MXhvX01tdEsyU2dzejBHLVFTT0hQQTJUM3plSmdfc3QxVFlieFA2Q2xNSGtKcWFWZ1RySHhCci05UHQ0eWJUMFFxZWxw?oc=5","date":"2025-12-15","type":"deal","source":"Contract Pharma","summary":"SOBI Agrees to Acquire Arthrosi Therapeutics - Contract Pharma","headline":"SOBI Agrees to Acquire Arthrosi Therapeutics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-01","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-19","type":"pipeline","source":"simplywall.st","summary":"Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has Caught The Eye Of Investors - simplywall.st","headline":"Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has Caught The Eye Of Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNQTlsTV9FN0dfZi1RY3BSdTByYUJ5Q1VlT045LVB6ZC00WkhxemlUcWJSX09JbVRCeEx1WGZZN3pHUlhLYy03TnFoOEJobmxWUk82WEU1UTNuY0lGQ3VYMzFwajF0SG94bDR4V2x2ZlFJcWRJeU9kMXJLVExrSXU3ZU9sUVgzWDRxb29HVHZqTTFMRU9TQ1c5elFhZmIzSVBnU18tczBSM2otTjFRY0ZUeHFB?oc=5","date":"2025-07-16","type":"pipeline","source":"Bloomberg.com","summary":"Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’ - Bloomberg.com","headline":"Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1nWWNkTGo1bEhWemNZUzBIY0hHTUs5MUp0ZVktVFFrOVVfa2x3TGpxcHF3c19GNUhvU2VpbWpYbzNPdmNIR294d3N1TVhMejg1U0JrNXU5REZiRzU3TDIwMmZDeGhwWTlXSDRwU1Jn0gFyQVVfeXFMT1cwbFFvNEZUZG55MTFTUGpJUHhES1QyWlJYS3RXaTB2a1YxUm1hbkNpQmRDaEhRUmlXTzdVZ2l4Zlo1YVpZdHdNZFZJdnhmMnZ6SFhiRXgzcGNKN1AwLUtHSWhaY0pqZEZLWlRUSUZXWHdB?oc=5","date":"2024-04-18","type":"pipeline","source":"koreabiomed.com","summary":"Handok and Swedish Orphan Biovitrum launch joint venture in Korea - koreabiomed.com","headline":"Handok and Swedish Orphan Biovitrum launch joint venture in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxObFV1Tm1Sb2J5Z25DdmYzLWM1ejdFdWxEX2YyaGkwRTlDZ1JCb05ka24xVDlvdm51eDlBTUlGeEx2dTVSOWNHdUJtdmJidWJ6UGFLMF9keWFLZm5pWENHa3NWU0o2aE1zMmx2RVJDdVcyWWdGaGZUQldVZlBnZzZVX05TdTRQNktLbjFvcFlZMjhzNHhTTy1mOUVVLWFONFJKdjltRWRzeUNER2FkalNTRUxQb09rLVBxSUZ1dzV0SmRHUHVPU1I2RnFRNDVLOFBUZ2JwR2Jn?oc=5","date":"2022-10-06","type":"pipeline","source":"DCAT Value Chain Insights","summary":"Women Leaders in Pharma Interview: Tarita Qveflander, Sobi – Swedish Orphan Biovitrum AB - DCAT Value Chain Insights","headline":"Women Leaders in Pharma Interview: Tarita Qveflander, Sobi – Swedish Orphan Biovitrum AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOUW9MNkh4UHN6MFBNLXB1Nk9NR2d3SjI0VUtyZXdmbEZuNHdHeWszWG5LMUIzX2plM3FYaHlLNVJFeFZpNmRNSnVLbFF5TzI1WHM1LVJpaTVGdkg1UjZqOWFyWXZKbkZSRUVydGRoLUpHaERpMFpCT2NDa1NFMnlzaWFnaVE3bW1Kd3JqYzBmM0d2bW5FTU8wckZBLUdGc29NZW95cUhXM1N4WFZHQlVVZzhvd0pnY3k1dWcxVnJXc1pSb1VpdFlz?oc=5","date":"2021-12-03","type":"deal","source":"Fierce Pharma","summary":"AstraZeneca blocks investor group's $7.6B buyout of rare disease specialist Sobi: report - Fierce Pharma","headline":"AstraZeneca blocks investor group's $7.6B buyout of rare disease specialist Sobi: report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPd2UtbkpFN3phbmZuamJUTm9LdEJWcmFyR0hraDVIenZseUMtdUJaaVRhY3hBLVU1eWFhUHZCd0RoYjVzWWpRaXlXVWZ0V09ITEkxeXJPT014SDdmWmw4QU9GbHIwN0hIMzhUQVVUb0tsbGhrRHlUOW1Qbzd1d2wxWFF5LUdxcHo0WjV2dUtxNWVRZEFsMWUxVnNjS3YxUHFDdm9hWkhWTVVmWHRkR1BRRQ?oc=5","date":"2018-01-25","type":"pipeline","source":"sobi.com","summary":"Sobi Names Holly May Vice President of Sales and Marketing in United States - sobi.com","headline":"Sobi Names Holly May Vice President of Sales and Marketing in United States","sentiment":"neutral"}],"patents":[],"drugCount":18,"phaseCounts":{"marketed":5,"phase_1":5,"phase_3":6,"discontinued":1,"phase_2":1},"enrichmentLevel":0,"visitCount":9,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}